Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 19, 2025 • 4:11 PM ET

Date/Time Source News Release
06/18/2025 07:30 AM EDT Newsfile NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
06/02/2025 09:55 AM EDT Canada Newswire Canadian Investment Regulatory Organization Trade Resumption - NGEN
06/02/2025 09:52 AM EDT PR Newswire Canadian Investment Regulatory Organization Trading Halt - NGEN
06/02/2025 07:00 AM EDT GlobeNewswire NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
05/23/2025 10:32 AM EDT Canada Newswire Canadian Investment Regulatory Organization Trade Resumption - NGEN
05/23/2025 10:28 AM EDT PR Newswire Canadian Investment Regulatory Organization Trading Halt - NGEN
05/21/2025 07:30 AM EDT Newsfile NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
05/16/2025 04:30 PM EDT Newsfile NervGen Pharma Grants Stock Options
05/15/2025 07:30 AM EDT Newsfile NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
05/07/2025 07:30 AM EDT Newsfile NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Page

Additional News

As of June 19, 2025 • 4:11 PM ET

Date/Time Source News Release
05/21/2025 11:49 AM EDT Baystreet NervGen, Sprott Climb to 52-Week Highs on News
02/13/2024 04:10 PM EST Motley Fool Canada 3 Healthcare Stocks to Buy and Hold for the Next 10 Years
09/08/2022 04:47 PM EDT News Direct Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
Page
  • 1

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.